Literature DB >> 21686558

Thrombotic thrombocytopenic purpura following zoledronic acid infusion with a fatal outcome.

Sanjay K Bhadada1, Anil Bhansali, Sambit Das, Ananthraman R, Sudhakar D Rao.   

Abstract

A 56-year-old woman presented with generalised bone pain with bone mineral density showing severe osteoporosis for which she received a single 4 mg infusion of zoledronic acid (ZA). On the second day following the infusion, she developed fever with altered sensorium. A complete blood count showed anaemia and thrombocytopenia with peripheral blood smear repeatedly showing schistocytes, anisopoikilocytes and target cells. Serum biochemistry revealed elevation of serum creatinine at 1.5 mg/dl. In view of microangiopathic haemolytic anaemia, fever, renal insufficiency, neurological abnormality and thrombocytopenia, the patient was presumed to have developed thrombotic thrombocytopenic purpura (TTP). Accordingly, a combination therapy with glucocorticoids and fresh frozen plasma transfusion was begun pending plasmapharesis. She manifested a fluctuating level of mental status with progressive purpuric and ecchymotic lesions and she sustained cardiorespiratory arrest from which she could not be revived. The temporal sequence of events following ZA infusion with typical manifestations of TTP strongly suggests ZA as the most probable cause of her fatal TTP.

Entities:  

Year:  2009        PMID: 21686558      PMCID: PMC3029861          DOI: 10.1136/bcr.09.2008.0923

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

1.  Renal failure with the use of zoledronic acid.

Authors:  Jennie T Chang; Lanh Green; Julie Beitz
Journal:  N Engl J Med       Date:  2003-10-23       Impact factor: 91.245

2.  Zoledronic acid-associated thrombotic thrombocytopenic purpura.

Authors:  G Ferretti; M C Petti; P Carlini; M Zeuli; A Picardi; G Meloni; E Bria; P Papaldo; A Fabi; F Cognetti
Journal:  Ann Oncol       Date:  2004-12       Impact factor: 32.976

3.  [Avascular osteonecrosis of the jaws induced by diphosphonates].

Authors:  Damien Lannoy; Bertrand Decaudin; Frédérique Barrier; Maxime Bemba; Laurence Wierre; Jean-Michel Pignon; Sandrine Horrent; Jean-Pierre Résibois; Marc Wetterwald; Pascal Odou
Journal:  Therapie       Date:  2006 Jul-Aug       Impact factor: 2.070

4.  Bisphosphonates inhibit breast and prostate carcinoma cell invasion, an early event in the formation of bone metastases.

Authors:  S Boissier; M Ferreras; O Peyruchaud; S Magnetto; F H Ebetino; M Colombel; P Delmas; J M Delaissé; P Clézardin
Journal:  Cancer Res       Date:  2000-06-01       Impact factor: 12.701

5.  Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis.

Authors:  Dennis M Black; Pierre D Delmas; Richard Eastell; Ian R Reid; Steven Boonen; Jane A Cauley; Felicia Cosman; Péter Lakatos; Ping Chung Leung; Zulema Man; Carlos Mautalen; Peter Mesenbrink; Huilin Hu; John Caminis; Karen Tong; Theresa Rosario-Jansen; Joel Krasnow; Trisha F Hue; Deborah Sellmeyer; Erik Fink Eriksen; Steven R Cummings
Journal:  N Engl J Med       Date:  2007-05-03       Impact factor: 91.245

  5 in total
  2 in total

1.  Spontaneously recovered severe thrombocytopaenia following zoledronic acid infusion for osteoporosis.

Authors:  Pooja Kulkarni; Terra Cushman; Vijayalakshmi Donthireddy; Sudhaker Rao
Journal:  BMJ Case Rep       Date:  2016-02-03

2.  Osteonecrosis of jaw associated with bisphosphonate use.

Authors:  Ashu Rastogi; Vidya Rattan; Sanjay Kumar Bhadada
Journal:  Indian J Endocrinol Metab       Date:  2012-05
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.